Anti-cancer Properties of Myricetin Against HT-29 Colon Cancer Cells Through Regulation of RIPK1/RIPK3 Signaling Pathway
Jentashapir Journal of Cellular and Molecular Biology · 2022
DOI: 10.5812/jjcmb-129878 ↗Kurz gefasst
Fachartikel in der Zeitschrift Jentashapir Journal of Cellular and Molecular Biology, 2022. Verfasst von Hadis Alidadi und 4 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Myricetin (MCN), a dietary flavonoid, is present in walnuts, fruits, vegetables, tea, and berries and has been suggested as an anti-inflammatory, antiplatelet, antimicrobial, antioxidant, and antiviral drug.
Objectives
This study aimed to investigate whether the necroptosis pathway involves the toxic impacts of myricetin (MCN) on the colon adenoma-carcinoma HT-29 cells.
Methods
For 48 hours, HT-29 cells were exposed to 50 µM MCN or three mM Necrosatine-1 (Nec-1), a necroptosis preventive. Apoptosis, cell viability, and expression of necroptosis-related genes, including mixed lineage kinase domain-like protein (MLKL), receptor-interacting protein kinase-1 (RIPK1), and receptor-interacting protein kinase-3 (RIPK3), were evaluated.
Results
MCN caused a noticeable decline in the survival of HT-29 cells. In contrast to the slight change in the apoptosis index in HT-29 cells, MCN considerably increased the necrosis index. MCN could enhance the expression of MLKL, RIPK1, and RIPK3 in the HT-29 cells. The co-treatment of MCN with Nec-1 resulted in a significant elevation in HT-29 cell survival. Nec-1 could decrease the necrosis index and expression of necroptosis-related proteins in the MCN-exposed HT-29 cells.
Conclusions
These findings demonstrated that MCN effectively induced cell death in HT-29 cells by activating the necroptosis pathway.
Zitieren
APA
Alidadi, H., Samimi, A., Karami, M. A., Khorsandi, L., & Ashtari, A. (2022). Anti-cancer Properties of Myricetin Against HT-29 Colon Cancer Cells Through Regulation of RIPK1/RIPK3 Signaling Pathway. Jentashapir Journal of Cellular and Molecular Biology. https://doi.org/10.5812/jjcmb-129878
Vancouver
Alidadi H, Samimi A, Karami MA, Khorsandi L, Ashtari A. Anti-cancer Properties of Myricetin Against HT-29 Colon Cancer Cells Through Regulation of RIPK1/RIPK3 Signaling Pathway. Jentashapir Journal of Cellular and Molecular Biology. 2022. doi:10.5812/jjcmb-129878
BibTeX
@article{Alidadi2022,
author = {Alidadi, Hadis and Samimi, Azin and Karami, Masoud Ali and Khorsandi, Layasadat and Ashtari, Atefeh},
title = {Anti-cancer Properties of Myricetin Against HT-29 Colon Cancer Cells Through Regulation of RIPK1/RIPK3 Signaling Pathway},
journal = {Jentashapir Journal of Cellular and Molecular Biology},
year = {2022},
doi = {10.5812/jjcmb-129878}
}
EUVIMED